OmniAb (OABI) Insider Jennifer Cochran Sells 20,000 Shares

Jennifer Cochran sold 20,000 shares of OmniAb, Inc. on June 17, 2026. Shares of OmniAb, trading under the ticker OABI on the NasdaqGM, were priced at $2.34 on Friday.

Insider Buying and Selling at OmniAb, Inc.

Jennifer Cochran sold 20,000 shares of OmniAb, Inc. on June 17, 2026. This transaction was not part of a pre-planned trading program. On the same day, Carolyn Bertozzi sold 20,000 shares and John Higgins bought 20,000 shares.

Other Institutional Activity in OmniAb, Inc.

Institutional investors have been adjusting their stakes in OmniAb, Inc. BlackRock, Inc. increased its holdings by 41,900 shares, bringing its total to 8,106,881 shares valued at about $12.7 million. Cadian Capital Management reduced its position by 277,825 shares, ending with 4,157,129 shares worth approximately $6.5 million. Vanguard Capital Management LLC opened a new position with 3,993,652 shares valued at $6.27 million. Geode Capital Management, LLC added 202,887 shares, raising its total to 2,925,579 shares with a value of $4.59 million.

OmniAb, Inc. Stock Down 47.7%

As of Friday, shares of OmniAb, Inc. (NasdaqGM: OABI) traded at $2.34. The company, with a market capitalization of around $339.2 million, operates in the biotechnology sector. OmniAb's stock has seen a 52-week low of $1.30 and a high of $2.79, with a 50-day moving average of $1.97 and a 200-day moving average of $1.80. The company has a forward P/E ratio of -7.26, reflecting its unprofitability.

Recent Earnings

OmniAb, Inc. reported revenue of $28.9 million, with a modest revenue growth rate of 2.47%. The company is not currently profitable, as indicated by its negative net margin of -187.6% and a return on equity of -20.25%. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

Several analysts have maintained their positive outlook on OmniAb, Inc. HC Wainwright & Co. reiterated a "buy" rating with an $11.00 price target on March 19, 2025. Benchmark also repeated a "buy" rating, setting a target of $6.00 on May 12, 2025. The consensus target price among analysts is approximately $7.33, based on six opinions.

About OmniAb, Inc.

OmniAb, Inc. is a biotechnology company based in Emeryville, California. It licenses its discovery research technology to pharmaceutical and biotech firms, as well as academic institutions, to aid in the development of therapeutics. The company's platform uses genetically modified animals to generate optimized antibodies for drug development. It employs a range of technologies, including OmniRat, OmniChicken, and OmniMouse, to facilitate the discovery of human-sequence antibodies.

Bottom Line

Jennifer Cochran's recent sale of OmniAb shares is part of ongoing trading activity within the company. Investors keep a close watch on OmniAb, Inc. due to its innovative biotechnology platform and active institutional interest. Remember, insider transactions are disclosed after the fact and may not indicate future actions or current positions.